Lynx1 Capital Management LP → Neuphoria Therapeutics Inc. NEUP

Item 4 of the Schedule 13D is hereby amended and supplemented as follows: On December 26, 2025, the Reporting Persons made an offer to the Board to acquire, through one or more managed investment funds and vehicles affiliated with the Investment Manager, certain intellectual-property-related assets of the Company in an all-cash transaction, or if the Company prefers, through the delivery by the Reporting Persons to the Company of shares of Common Stock of the Company with equivalent value (the "IP Rights Proposal"). The IP Rights Proposal is subject to the Reporting Persons' due diligence and agreement on definitive documentation for the acquisition. Neither the Reporting Persons nor the Company is obligated to complete a transaction in connection with the IP Rights Proposal, and there can be no assurance (i) as to the outcome of any discussions related to the IP Rights Proposal; (ii) that any agreement will be reached between the Company and the Reporting Persons; (iii) that the terms of any transaction will not differ from the terms contemplated by the IP Rights Proposal; or (iv) that the Reporting Persons will not from time to time make offers for other assets of the Company. The IP Rights Proposal may result in one or more of the actions specified in clauses (a)-(j) of Item 4 of Schedule 13D, including the disposition of securities of the Company and/or a sale or transfer of a material amount of the Company's assets. The Reporting Persons may further consider pursuing other plans, proposals or other courses of action with the Company's management, the Board, other Company stockholders, advisors or other persons which could relate to, or result in, several of the matters referred to in clauses (a)-(j) of Item 4 of Schedule 13D.